Table 1 Patient characteristics and results of salvage CBT

From: Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation

Case

Age/sex

Disease

Days from the failed SCT

Preparative regimen a , b

Time to engraftment (days)

Infection before salvage CBT

Current status (days, cause of death)

     

Neutrophil

Platelet

  

1

61/M

MDS

61

Flu125/Mel80/TBI (2)

20

13

Bacteremia (Klebsiella pneumoniae)c, pulmonary mycosis

D (day 288, relapse)

2

37/F

ALL

41

Flu120/Mel40

20

No

No

D (day 54, EBV-PTLD)

3

40/M

PTCL

44

Flu125/CY2000/TBI (2)

No

27

Pneumonia (Burkholderia cepacia)d, viremia (CMV)d

D (day 37, pneumoniad)

4

18/F

AML

44

Flu120/Mel80

14

52

FN

A (day 1652)

5

41/M

AML

28

Flu125/Mel80/TBI (2)

22

24

Bacteremia (Streptococcus mitis)

A (day 201)

6

33/M

AML

49

Flu125/Mel80/TBI (4)

22

39

Bacteremia (Corinebacterium), pulmonary mycosisc

A (day 2334)

7

27/F

AA

78

Flu120/Mel80/TBI (4)

21

42

Hemorrhagic cystitis (BK virus)c

A (day 1549)

8

50/F

AA

38

Flu125/Mel80/TBI (4)

17

33

FN

A (day 3991)

  1. Abbreviations: A=alive; AA=aplastic anemia; CBT=cord blood transplantation; D=dead; F=female; FN=febrile neutropenia; HHV-6=human herpes virus 6; M=male; MDS=myelodysplastic syndrome; PTCL=peripheral T-cell lymphoma; PTLD=post-transplant lymphoproliferative disorder; SCT=stem cell transplantation.
  2. aThe numbers following the cytotoxic agents indicate the total infused dose (mg/m2).
  3. bThe numbers in parentheses indicate the dose of TBI (Gy).
  4. cRecurrence of the infection after salvage CBT.
  5. dCarryover infection.
Back to article page